Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

O4139

Orlistat

≥98% (HPLC), solid, lipase inhibitor

Synonyme(s) :

(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C29H53NO5
Numéro CAS:
96829-58-2
Poids moléculaire :
495.73
UNSPSC Code:
41106300
PubChem Substance ID:
24724564
NACRES:
NA.77
MDL number:
MFCD05662360
Assay:
≥98%
Form:
solid
Quality level:
200
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Orlistat, ≥98%, solid

biological source

synthetic (organic)

Quality Level

200

assay

≥98%

form

solid

color

white

mp

<50 °C

solubility

DMSO: 19 mg/mL

originator

Roche

storage temp.

2-8°C

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513), PNLIP(5406)

General description

Orlistat acts as a gastric lipase inhibitor that reduces fat absorption.

Application

Orlistat has been used as an inhibitor:
  • of fatty acid synthase in long-term estrogen-deprived (LTED) variant cell lines
  • of lipase in screening lipase inhibition by raspberry extract
  • in in vitro pancreatic lipase activity assay

Biochem/physiol Actions

Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis.
Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Solution is not completely clear, small particles may remain floating.

Still not finding the right product?

Explore all of our products under

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000465528
0000385434
0000494189
0000465530
0000432435

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Contenu apparenté

Inhibitory effect of raspberries on starch digestive enzyme and their antioxidant properties and phenolic composition
Zhang L, et al.
Food Chemistry, 119(2), 592-599 (2010)
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial
Chanoine JP, et al.
JAMA : The Journal of the American Medical Association, 293(23), 2873-2883 (2005)
Shiva Kant et al.
Biochimica et biophysica acta, 1840(1), 294-302 (2013-09-26)
Orlistat, a fatty acid synthase (FASN) inhibitor, has been demonstrated to inhibit tumor cell survival. However, the mechanism(s) of its tumor growth retarding action against malignancies of hematological origin remains unclear. It is also not understood if the antitumor action
Afficher tous les articles scientifiques apparentés